Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + carboplatin + nab-paclitaxel first-line treatment for metastatic PD-L1-positive triple-negative breast cancer
2024-519514-31-00Phase 2Authorised
- Sponsor
- Consorzio Oncotech
- Start
- Jan 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, carboplatin and paclitaxel in breast cancer, sponsored by Consorzio Oncotech. Primary endpoint: Overall survival at 2 years. Planned start Jan 2025; status: authorised.
02
Drugs
atezolizumabcarboplatinpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-519514-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519514-31-00.